Getting your player ready...
PRINCETON, N.J. — India’s biggest maker of generic drugs has gotten approval to launch a generic version of cholesterol blockbuster Lipitor, which lost U.S. patent protection Wednesday.
Ranbaxy Laboratories has had major manufacturing-quality deficiencies since 2006, leading the U.S. Food and Drug Administration to hold up approval of Ranbaxy’s version of generic Lipitor, the top-selling drug ever.
The FDA announced approval Wednesday night.
